Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia
The purpose of this study is to compare efficacy and safety of add-on treatment with a moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset schizophrenia patients who suffer from significant…
- Trial name
- SATROS (NCT01459029)
- Testing
- D-serine
- Where
- 2 sites in Israel
- Volunteers
- 54 people
- Sponsor
- Hadassah Medical Organization
Schizophrenia, Schizoaffective Disorder
Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis
Multifamily group psychoeducation [MFG] and group cognitive behavioral therapy [GCBT] are evidence-based treatments for first episode psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depression With Psychotic Features
- Trial name
- NCT01570972
- Testing
- Group Cognitive Behavioral Therapy, Multifamily Group Psychoeducation
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- University of Arizona
Schizophrenia
A Study to Evaluate the Effect of KarXT on Urological Safety
The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.
- Trial name
- NCT07221877
- Testing
- Xanomeline/trospium chloride
- Where
- 16 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Healthy Control Subjects, Schizophrenia Diagnosis
Understanding Lifespan Trajectories of Social Cognition, Brain Microstructure and Iron Dysregulation in Schizophrenia
This study aims to better understand how schizophrenia may affect social thinking, emotion regulation, brain function, and biological processes over time. Two groups will take part in the study: 1.
- Trial name
- NCT07856381
- Where
- Austria
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Psychotic Disorders, Recent-Onset Psychosis
Effects of a Peer-facilitated, Acceptance-based Self-learning for Illness Management (PASIM) Program
Psychosis is a very disabling mental illness with a wide range of dysregulations and disruptions in cognition, emotions, and behaviors, resulting in poor functioning and frequent relapses, especially in the first five years of…
- Trial name
- NCT07129369
- Testing
- PASIM program, Psychoeducation, Usual-Care-only
- Where
- 2 sites in China
- Volunteers
- 186 people
- Sponsor
- Chinese University of Hong Kong
Dementia, Depression
Geriatric Psychiatry and Pharmacovigilance
The purpose of this observational multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients.
- Conditions
- Dementia, Depression, Schizophrenia, Psychosomatic Disorders
- Trial name
- GAP (NCT01858857)
- Where
- 5 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Hannover Medical School
Metabolic Syndrome X, Schizophrenia
Metabolic Syndrome in Patients With First-episode Schizophrenia
The metabolic syndrome (MetS) is highly prevalent in patients with schizophrenia and is a major risk factor of type-2 diabetes, cardiovascular disease and early death.
- Trial name
- NCT00957294
- Where
- Denmark
- Volunteers
- 203 people
- Sponsor
- Aarhus University Hospital
Schizophrenia, Bipolar Disorder
CSP #572 - Genetics of Functional Disability in Schizophrenia and Bipolar Illness
The purpose of this study is to detect genetic associations for the development of schizophrenia (SZ) and bipolar illness (BP) by comparing Veterans with these diseases to "psychiatrically healthy" Veterans from Veterans Health…
- Trial name
- NCT01149551
- Where
- 25 sites in United States
- Volunteers
- 9,356 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Negative Symptoms in Schizophrenia
Dance and Movement Therapy in Patients With Schizophrenia
Introduction: Schizophrenia is a mental disorder that starts at a young age and progresses with positive (hallucination, delusion) and negative (decreased emotional participation, reluctance) symptoms.
- Conditions
- Schizophrenia, Negative Symptoms in Schizophrenia, Disabilities Mental, Dance Therapy
- Trial name
- DMTinSchizo (NCT05500651)
- Testing
- Dance and Movement Therapy (DMT)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Amasya University
Schizophrenia
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
- Trial name
- NCT03817502
- Testing
- Cariprazine
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Gedeon Richter Plc.
Schizophrenia, Cardiovascular Risk Factor
Effectiveness of a Cardiovascular Risk Intervention Program in Patients With Schizophrenia (PRISCA)
The main objective is to determine the effectiveness of a program which consists of multidisciplinary, intensive and individualized interventions, carried out by a group of health professionals (psychiatrist, psychologist, mental…
- Trial name
- PRISCA (NCT04276012)
- Testing
- Multifactorial intervention
- Where
- Spain
- Volunteers
- 130 people
- Sponsor
- Dr. Pere Roura-Poch
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
Schizophrenia
Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders
The current diagnostic criteria for schizophrenia and other psychotic disorders are relatively broad and lack precision. Therefore, distinct diseases may be grouped together under the same diagnostic category, although these…
- Trial name
- NeuroSplitsz (NCT03649581)
- Testing
- compare the two groups of schizophrenic patients, compare the two groups of schizophrenic patients versus volunteers
- Where
- France
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia
The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia
The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.
- Trial name
- NCT01493622
- Testing
- minocycline
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Central South University
Schizophrenia
Integrated Coping and Awareness Training
Integrated Coping and Awareness Therapy is a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g.
- Trial name
- I-CAT (NCT02400502)
- Testing
- I-CAT Therapy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Schizoaffective Disorder
Sodium Nitroprusside in Early Course Schizophrenia
Peripheral inflammation and microvascular dysfunction are central to the pathophysiology of schizophrenia (SZ). Retinal imaging allows for the accurate quantitative assessment of the condition of retinal microvessels, and early…
- Trial name
- NCT04986072
- Testing
- Sodium Nitroprusside, 5% Dextrose solution
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Beth Israel Deaconess Medical Center
Schizophrenia, Schizoaffective Disorder
The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study
The aim of the project is to investigate the use of raloxifene (a new form of estrogen) as a treatment for schizophrenia in postmenopausal women.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00206557
- Testing
- Raloxifene, Estradiol/dyhydroprogestrone
- Where
- Australia
- Volunteers
- 60 people
- Sponsor
- The Alfred
Psychoses, Substance-Induced
Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids
Ketamine, an FDA approved anesthetic agent, is becoming the sedative/analgesic of choice for emergency sedation in children because it causes deep sedation with minimal respiratory depression in comparison to other available…
- Trial name
- NCT00205712
- Testing
- Ketamine, Dexmedetomidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia.
- Trial name
- NCT06179108
- Testing
- LB-102
- Where
- 25 sites in United States
- Volunteers
- 359 people
- Sponsor
- LB Pharmaceuticals Inc.
Psychotic Disorder
Mobile After-Care Support App: Pilot RCT
The overall aim of this program of research is to refine and test the feasibility and acceptability of a newly developed mobile device-delivered app, called Mobile After-Care Support (MACS), to improve patients' coping and…
- Trial name
- MACS-RCT (NCT03955250)
- Testing
- Mobile After-Care Support (MACS) app, Mobile app attention control
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Butler Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.